Nurmohamed M, Choy E, Charles-Schoeman C, et al. Impact of Tofacitinib Treatment Compared with Placebo or Methotrexate on Cardiovascular Risk Scores in Six Phase 3 Randomized Controlled Trials. ACR 2017, abstract 2966.
Olokizumab plus methotrexaat: veiligheid en effectiviteit op de lange termijn
dec 2024 | RA